- Home
- XAIR vs IMNN Comparison
XAIR vs IMNN Comparison
Compare XAIR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | IMNN |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 11.0M |
| IPO Year | 2015 | 2000 |
Fundamental Metrics
Financial Performance| Metric | XAIR | IMNN |
|---|---|---|
| Price | $0.78 | $2.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $182.61 |
| AVG Volume (30 Days) | ★ 163.9K | 17.3K |
| Earning Date | 02-13-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.37 |
| 52 Week High | $3.78 | $9.32 |
Technical Indicators
Market Signals| Indicator | XAIR | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 35.79 |
| Support Level | $0.76 | $0.43 |
| Resistance Level | $1.25 | $3.16 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.95 | 11.64 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).